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Analysis of Pseudoxanthoma Elasticum–Causing
Missense Mutants of ABCC6 In Vivo; Pharmacological
Correction of the Mislocalized Proteins
Viola Pomozi1, Christopher Brampton2, Krisztina Fu¨lo¨p1, Li-Hsieh Chen2, Ailea Apana2, Qiaoli Li3,
Jouni Uitto3, Olivier Le Saux2,4 and Andra´s Va´radi1,4
Mutations in the ABCC6 gene cause soft-tissue calcification in pseudoxanthoma elasticum (PXE) and, in some
patients, generalized arterial calcification of infancy (GACI). PXE is characterized by late-onset and progressive
mineralization of elastic fibers in dermal, ocular, and cardiovascular tissues. GACI patients present a more severe,
often prenatal arterial calcification. We have tested 10 frequent disease-causing ABCC6 missense mutants for the
transport activity by using Sf9 (Spodoptera frugiperda) cells, characterized the subcellular localization in MDCKII
(Madin–Darby canine kidney (cell line)) cells and in mouse liver, and tested the phenotypic rescue in zebrafish.
We aimed at identifying mutants with preserved transport activity but with improper plasma membrane
localization for rescue by the chemical chaperone 4-phenylbutyrate (4-PBA). Seven of the mutants were
transport-competent but mislocalized in mouse liver. The observed divergence in cellular localization of mutants
in MDCKII cells versus mouse liver underlined the limitations of this 2D in vitro cell system. The functionality of
ABCC6 mutants was tested in zebrafish, and minimal rescue of the morpholino-induced phenotype was found.
However, 4-PBA, a drug approved for clinical use, restored the plasma membrane localization of four ABCC6
mutants (R1114P, S1121W, Q1347H, and R1314W), suggesting that allele-specific therapy may be useful for selected
patients with PXE and GACI.
Journal of Investigative Dermatology advance online publication, 12 December 2013; doi:10.1038/jid.2013.482
INTRODUCTION
Ectopic calcification occurs in various common conditions,
such as diabetes, hypercholesterolemia, and chronic renal
insufficiency, as well as in certain genetic conditions. Pseu-
doxanthoma elasticum (PXE, OMIM 26480) is one of these
heritable disorders characterized by late-onset and progres-
sive mineralization of elastic fibers in dermal, ocular, and
cardiovascular tissues. Generalized arterial calcification of
infancy (GACI, OMIM 614473) also presents a calcification
phenotype with characteristics similar to the arterial
phenotype of PXE, although it is more severe in some
instances with prenatal mineralization of the arterial blood
vessels. Loss-of-function mutations in ABCC6 cause both PXE
and a subset of GACI cases (most GACI patients carry
mutations in the Ectonucleotide Pyrophosphatase/Phospho-
diesterase 1 (ENPP1) gene) (Nitschke et al., 2012; Li et al.,
2013). ENPP1 is a cell surface enzyme generating inorganic
pyrophosphate, a solute that regulates cell differentiation and
serves as an essential physiologic inhibitor of calcification.
Interestingly, heterozygous ABCC6 mutations confer an
increased susceptibility to cardiovascular diseases (Trip
et al., 2002; Ko¨blo¨s et al., 2010; Martin et al., 2011),
although this finding is somewhat controversial (Hornstrup
et al., 2011). ABCC6 is primarily expressed in the liver and at
a lower level in kidneys. The corresponding protein is
localized in the basolateral plasma membrane (Pomozi
et al., 2013), and it facilitates the sinusoidal efflux of an
unknown metabolite(s) toward the bloodstream. Because the
ectopic calcification occurs in peripheral tissues, PXE is
considered as metabolic disease (Jiang et al., 2009; Uitto
et al., 2010). On the same line of reasoning, this might be true
for ABCC6-connected GACI as well.
The number of disease-causing ABCC6 variants identified
thus far largely exceeds 300 (Pfendner et al., 2007), and the
mutation spectra of ABCC6 in PXE and in GACI overlap. In
spite of this large number of mutations, no clear genotype–
phenotype correlation was established for PXE (Le Saux et al.,
2001; Chassaing et al., 2005; Pfendner et al., 2007). In the
light of the phenotype divergence between the PXE- and
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ABCC6-related GACI patients, notably the severity and the
affected tissues, the lack of clear correlation is not surprising.
Most of the disease-causing mutations in ABCC6 are
missense, and a significant fraction of these clusters in
areas critical to the physiological function of the protein
(Fu¨lo¨p et al., 2009; Le Saux et al., 2011). In fact, amino-
acid substitutions in ABC transporter proteins, such as
ABCC6, tend to result in the loss of function either through
changes in the catalytic/transport activity, in the intracellular
trafficking, the conformational stability, or any combination
thereof.
We have characterized several ABCC6 mutants with sub-
stantial residual transport activity but abnormal intracellular
processing, that is, with no or only partial plasma membrane
localization (Le Saux et al., 2011). Deciphering consequences
of disease-associated missense mutations may assist in the
development of individualized, mutation-based therapeutic
applications. Specifically, these mutant proteins appear as
excellent candidates for ‘‘folding-correction’’ in order to adjust
their intracellular trafficking. Indeed, we have identified
one such mutant, R1314W, whose cellular localization
was normalized using the chemical chaperone sodium
4-phenylbutyrate (4-PBA) in both in vitro and in vivo
experiments. In contrast to pharmacoperones, such chemical
chaperones have the notable advantage of promoting folding
with no direct interaction with the proteins, thus not
interfering with their function (Ulloa-Aguirre and Conn,
2011). In support of this approach, several studies have
shown that 4-PBA can partially rescue the intracellular
trafficking of the frequent DeltaF508 variant of ABCC7/CFTR
(cystic fibrosis transmebrane regulator) and maybe some of its
channel function (Rubenstein and Zeitlin, 2000). Of particular
interest is that 4-PBA is also approved by US Food and Drug
Administration for clinical use in urea cycle disorders and
thalassemia (Dover et al., 1992; Perrine et al., 1993; Maestri
et al., 1996). Many membrane proteins with disease-causing
mutations have also been successfully subjected in vitro to
4-PBA treatment, resulting in marked improvement of their
folding/trafficking: ABCA1 (Sorrenson et al., 2012), ABCA3
(Cheong et al., 2006), LDL-receptor (Tveten et al., 2007),
BSEP11/ABCB11 (Hayashi and Sugiyama, 2007, 2009; Lam
et al., 2007), ATP7B (van den Berghe et al., 2009), ATP8B1
(van der Velden et al., 2010), and ATP-sensitive potassium
channel/ABCC8 (Powell et al., 2011).
In the present work, we have fully characterized 10 ABCC6
missense mutants associated with PXE and GACI with respect
to their transport activity, stability, and conformation/folding
both in vitro and in vivo for the purpose of evaluating their
rescue potential by 4-PBA. The in vitro testing was performed
in cell-free assays, as well as in cultures of polarized and
nonpolarized MDCKII (Madin–Darby canine kidney (cell line))
cells. The in vivo analysis relied on two complementary
animal models. First, the transient expression of the mutant
proteins in mouse liver was carried out to determine their
subcellular tissue localization, and second in zebrafish
embryo system (Li et al., 2010) to evaluate the rescue of the
morpholino-induced developmental phenotype provided by
the human ABCC6 variants.
RESULTS
We have generated 12 ABCC6 variants using PCR mutagen-
esis (Table 1), 11 of which are associated with PXE, 1 of which
is also a causative mutation in GACI. In addition to 10
missense mutants, R1141X was also used as a negative control
in certain experiments. Six of the mutants were partially
characterized in our previous studies (Ilia´s et al., 2002; Le
Saux et al., 2011). The disease-associated mutations were
selected for their frequency in PXE patients (S Terry of PXE
International, personal communication), by that in GACI
(Nitschke et al., 2012; Li et al., 2013), and by their
predicted localization in the homology model (Fu¨lo¨p et al.,
2009). Their positions in the membrane topology model are
indicated in Figure 1a. We also included an N-terminally
truncated version (delABCC6), lacking amino acids 2–275,
that is, domains TMD0 and L0. The mutated cDNAs
were cloned into baculovirus vector for Sf9 (Spodoptera
frugiperda) insect cell expression, into retroviral vector for
expression in MDCKII cells (Sinko´ et al., 2003), into the pLIVE
vector for liver-specific in vivo expression in mice, and into
Bluescript II SKþ vector for in vitro transcription of human
ABCC6 cDNA to mRNA for subsequent injection into
zebrafish embryos.
Biochemical characterization of transport activity
Inside-out vesicles of Sf9 cells expressing the human ABCC6
variants were used in the rapid filtration transport assay in the
presence of two model substrates: LTC4 (leukotriene C4)
(50 nM) and N-ethylmaleimide-glutathione (4mM, not shown).
As shown in Figure 1b, the wild-type (wt) ABCC6 is fully
functional in the biochemical transport assay, as shown earlier
(Ilia´s et al., 2002), and 7 of the 10 missense mutant variants
included in this study were also active as transporters. Two
missense variants (V1298F and G1321S) showed very little, if
any, transport activity (Ilia´s et al., 2002). The R1339C was
found to be unstable in Sf9 cells, similar to that shown earlier
(Le Saux et al., 2011), and its transport activity could not
be assayed. The delABCC6 mutant showed low transport
activity. The nonsense R1141X mutant was not expressed in
Sf9 cells.
Subcellular localization in vitro
Each mutant (with the exception of R1141X) was individually
expressed in MDCKII cells, which were then grown either on
plastic wells as nonpolarized cells or on Transwell filters,
which ensures development of monolayers of polarized cells.
The wtABCC6 was present predominantly in the plasma
membrane in both types of cell cultures, and specifically in
the basolateral compartment of the polarized cells (Figure 2,
columns 1 and 3). The delABCC6 was found to be entirely
intracellular in both cell culture types, thus serving as an
intracellular (‘‘incorrect’’) localization control. Eight of the ten
missense mutants when expressed in polarized and nonpolar-
ized MDCKII cultures did not show wt–like subcellular
localization (Figure 2, columns 1 and 3). In nonpolarized
cells, only S1121W and the transport-deficient V1298F were
targeted to the plasma membrane. In addition to these, three
other mutants, R1114P, R1138Q, and T1301I, were also
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found in the basolateral plasma membrane when expressed in
polarized MDCKII cells (Figure 2, columns 1 and 3).
Investigation of subcellular localization in vivo in mouse liver
ABC transporters are frequently studied in cultures of kidney-
derived MDCKII cells, but this cell type does not represent the
physiology of the liver where ABCC6 is primarily present.
Therefore, to determine subcellular localization of mutant
ABCC6 variants, we used hydrodynamic tail vein injection of
pLIVE vectors into normal C57BL/6J mice. The vectors con-
tained the appropriate cDNA constructs under the control of a
liver-specific mouse albumin promoter. As we have demon-
strated previously, we could achieve a high level of liver-
specific expression, whereas no human protein was detected
in other organs (Le Saux et al., 2011). Each mutant was
injected into at least three mice, and the livers were harvested
at 24 hours after injection. To detect possible intracellular
trafficking defects of the mutant ABCC6 proteins, expression
and the subcellular distribution of ABCC6 proteins in the liver
were determined by immunohistochemistry and confocal
microscopy, and 50–100 cells expressing the human protein
were individually imaged to assess subcellular localization. As
we have shown previously, the wtABCC6 is targeted to the
plasma membrane, and it shows colocalization with the
endogenous mouse Abcc6 (Figure 3, column 1), whereas
delABCC6 was intracellular. The R1459C and the transport-
inactive V1298F mutants were found in subcellular localiza-
tion identical to the wt, whereas all the other mutants showed
various degrees of intracellular localization, as illustrated in
Figure 3, column 1. Interestingly, S1121W, which showed wt–
like plasma membrane localization in both MDCKII expres-
sion systems, was mostly intracellular in mouse liver, similar
to delABCC6. It is worth noting that R1114P and R1138Q
mutants were found both intracellularly and in the plasma
membrane. The R1141X mutant was not expressed in the
mouse liver.
Rescue of the developmental phenotype of morpholino-silenced
zebrafish
Our earlier work indicated that both the mouse Abcc6 and
human ABCC6 mRNA provided a nearly complete rescue of
the developmental phenotype triggered by morpholino-
mediated silencing of the Abcc6a gene in zebrafish embryos
(Li et al., 2010; Zhou et al., 2013). In the present study, wt and
mutant human ABCC6 mRNAs were transcribed in vitro and
injected together with a morpholino into zebrafish embryos.
At least 100 embryos were injected for each mRNA variant. As
shown in Figure 4, the wt human ABCC6 rescues the zebrafish
phenotype, and statistical analysis shows that the extent of
rescue was 90.6% (Table 1). Next, the injection of the
nonsense R1141X mRNA showed that this mutant was
ineffective in rescuing the morpholino-mediated phenotype
(4.8%). Eight of the ten disease-causing missense mutants
were not able to counteract the effect of gene silencing by the
Abcc6a-specific morpholino (0–5.1% rescue). The efficacy of
S1121W was somewhat better (7.9%), whereas that of the
V1298F was significantly higher (32.0%). These data are
detailed in Table 1.
Pharmacological correction of ‘‘mistargeted’’ ABCC6 mutants
The main aim of this study was to evaluate the potential of the
chemical chaperone/corrector 4-PBA to restore the normal
intracellular trafficking of each mutant that retained substantial
transport activity. We performed these experiments both
in vitro in cell cultures and in vivo in mouse liver. Note that
this type of experiment was not performed in vivo with the
two inactive mutants, V1298F and G1321S, or with R1459C,
as this mutant was found in the plasma membrane without
4-PBA treatment. The effect of 4-PBA treatment on the mutants
expressed in nonpolarized or in polarized MDCKII cells
showed different results (see Figure 2, columns 2 and 4). For
instance, mutants Q1347H and R1459C were found mostly
intracellularly in nonpolarized and in polarized MDCKII cells,
yet the 4-PBA treatment resulted in plasma membrane
localization only when these two variants were expressed in
nonpolarized cells. More importantly, we found additional
discrepancies when the effect of 4-PBA was investigated in
mouse liver. No 4-PBA-induced plasma membrane rescue
was observed for R1138Q and T1301I in mouse liver, whereas
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Figure 1. Positions of the investigated mutants in the membrane topology
model of ABCC6 protein and their transport activity. (a) The model is based
on our earlier publication (Tusna´dy et al., 2006); the positions of the various
domains are indicated by horizontal arrows. Conserved sequence motifs, ABC
signatures, Q-loops, and Waker B motifs are colored, and the positions of
known disease-causing missense mutations are indicated with red color.
Arrows point to the positions of mutants investigated in the present study.
(b) Protein variants were expressed in Sf9 insect cell system, and their ATP-
dependent transport activity was assayed in the presence of 50 nM [3H]LTC4 as
substrate. Transport activity was compared with that of the wild-type (wt)
protein (100%). Each assay has been performed on two independent
membrane preparations in triplicate. LTC, leukotriene C4.
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the same compound was effective in nonpolarized MDCKII
cells (compare Figure 2 and Figure 3). As for the R1314W
mutant, 4-PBA treatment resulted in plasma membrane
targeting both in polarized and nonpolarized MDCKII cells,
as well as in mouse liver. 4-PBA treatment was also effective
in the case of Q1347H in vivo, while it facilitated plasma
membrane targeting only in nonpolarized MDCKII cells (but
not in polarized cell cultures). No plasma membrane targeting
was achieved in the case of mutant R1339C irrespective of
which experimental system was used.
We found that the same concentration of 4-PBA used in
MDCKII cell cultures was toxic to zebrafish, and further
experiments with this compound were not pursued.
The in vitro and in vivo localization data, along with those
obtained by the 4-PBA treatment, are summarized in Table 1.
DISCUSSION
In the present study, we characterized the transport activity,
stability, and conformation/trafficking of ten disease-causing
ABCC6 missense mutations associated with PXE and GACI
using in vitro and in vivo models. The results significantly
expand our understanding of the structural and functional
consequences of disease-causing mutations in an ABC trans-
porter, specifically ABCC6, as well as the model systems,
which were used to study this protein. We also demonstrated
the feasibility of pharmacological correction of certain
disease-causing missense mutants.
Interestingly, we found that the majority of the missense
ABCC6 variants (7 of 10) retained a high level of LTC4 and
N-ethylmaleimide-glutathione transport efficiency as deter-
mined by cell-free inside-out vesicles derived from Sf9 cells.
Of the three remaining mutants, only two displayed decreased
transport function (Figure 1b), whereas the other mutant could
not be stably expressed in Sf9 cells (R1339C). These results
suggested that the disease-causing ABCC6 missense mutations
that are not directly affecting transport and/or ATP catalytic
activity resulted primarily in lower stability and/or cytoplasmic
retention of the mutant proteins. To confirm this possibility,
we expressed this series of ABCC6 mutants and controls in
MDCKII cells, an in vitro model traditionally used in studies of
other ABC transporters. The MDCKII cells were cultured under
both nonpolarized and polarized conditions. We achieved a
good level of expression of the R1339C mutant in this culture
model. The results from these experiments revealed that the
cellular localization of the mutants was variable under
the polarized and nonpolarized condition, in the majority of
the mutants tested (7 out of 10), which highlighted the
influence of the polarization status of this in vitro model.
Additional divergence of the results was observed after the
treatment of the cultures with 1 mM 4-PBA, which was
Figure 2. Subcellular localization of ABCC6 variants expressed in MDCKII
(Madin–Darby canine kidney) cells and the effect of 4-phenylbutyrate (4-PBA)
treatment on their localization. ABCC6 was detected by immunofluorescence
using mAb M6-II7 (green color); anti-Na,K-ATPase pAb was used to detect
Na,K-ATPase as a plasma membrane localization marker (red color). Cells
overexpressing ABCC6 variants were grown with or without 1 mM 4-PBA either
on plastic (nonpolarized) or on Transwell membrane (polarized). Confocal
laser microscopy images were collected together with Z-stack images in the
case of polarized cell cultures. Bar¼20mm.
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intended to correct their cellular localization, as described
previously (Le Saux et al., 2011). For both mutants Q1347H
and R1459C, the chemical chaperone was effective in
correcting its cellular trafficking only in nonpolarized
cultures.
As ABCC6 has a specialized efflux function in the liver, we
extended our studies to in vivo models whereby we transiently
expressed the ABCC6 mutants in C57BL/6J mouse liver along
with positive and negative controls. As we previously showed
(Le Saux et al., 2011), a high degree of liver-specific transient
expression can be achieved in this fully differentiated organ in
adult mice. When we compared the cellular localization of
the mutants in polarized MDCKII cells with the liver of C57BL/
6J mice, divergence was observed in localization of six
ABCC6 variants (Table 1). Such discrepancy was further
observed when 4-PBA was used for treatment (Table 1). The
observed differences in localization of the same mutant after
treatment in polarized MDCKII cells versus mouse liver
underline the limitations of a 2D MDCKII cell culture system.
Therefore, we propose the use of hydrodynamic tail vein
injection of plasmids for localization studies of liver-specific
ABC proteins, such as ABCC6.
The second in vivo model, the zebrafish (Danio rerio), was
used to investigate the functionality of the ABCC6 disease-
causing mutants. The biological basis of this experimental
Figure 3. Subcellular localization of ABCC6 variants expressed in mouse liver
and the effect of 4-phenylbutyrate (4-PBA) treatment on their localization.
The human and mouse ABCC6/Abcc6 were detected on frozen sections by
immunofluorescence using mAb M6-II7 (green color) and the S-20 polyclonal
antibody (red), respectively. Mice received three intraperitoneal injections
of 4-PBA (100 mg/kg 1 per day) before performing hydrodynamic tail-vein
injections and received 6.25 mg ml1 4-PBA in drinking water during the
entire experiment.
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Figure 4. Rescue of the morpholino-induced phenotype by human ABCC6
mRNA in zebrafish embryos. Human ABCC6 cDNA variants were cloned into
Bluescript II SKþ vector, mRNA was generated by in vitro transcription, and
2–4 ng of mRNA was injected into B100 embryos together with 12–18 ng of
MO1 morpholino (MO1; for sequence, see Li et al., 2010). Animals were
photographed 3 days after injection. (a) Control animals injected with standard
control morpholino. (b) Animals injected with morpholino. (c) Animals
injected with morpholino and with wtABCC6 mRNA. (d) Animals injected with
morpholino and with ABCC6 R1141X mRNA. Wt, wild type.
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system was that both mouse Abcc6 mRNA (Li et al., 2010) and
human ABCC6 mRNA (Zhou et al., 2013) provided nearly
complete rescue of the morpholino-induced developmental
phenotype (see Figure 4). These observations indicated that, in
spite of the different phenotypes in zebrafish and in patients
with PXE or GACI, the fish and the human proteins fulfill a
similar transport function in the two organisms. Minimal level
of rescue was provided by the disease-causing mutants (0–
7.9%) irrespective of their transport activity or their cellular
localization, with the exception of V1298F (32.0%; Table 1).
This mutant showed correct plasma membrane localization in
mouse liver, but was otherwise transport deficient with very
low, if any, activity. We hypothesized that V1298F probably
possesses some residual transport activity of the endogenous
zebrafish substrate.
In addition, it is noteworthy that the PXE-associated mutant
R1459C (Chassaing et al., 2005) was found to be an active
transporter, and it localized in the plasma membrane in mouse
hepatocytes, suggesting that R1459C could be a neutral poly-
morphism rather than a disease-causing mutant. However, as
this variant could not rescue the zebrafish phenotype, it
probably is a genuine disease-causing mutant. The case of
R1459C illustrates the necessity of using multiple model
systems in parallel to study the functional consequences of
ABCC6 mutations.
The major finding of our study was that 4-PBA treatment
restored the plasma membrane localization of three transport-
competent missense mutants, R1114P, S1121W, and
Q1347H in mouse liver, in addition to R1314W, which
served as a positive control in the present study. Our data
indicate that the in vivo mouse model system provides the best
approach to answer the question of subcellular location of
ABCC6 and bodes well for the next stage of research, that is,
verifying whether the pharmacological correction of the
plasma membrane localization of candidate mutants results
in physiological rescue of ectopic calcification.
Over 50% of PXE patients harbor missense mutations, and
our results show that the majority of such mutations likely
cause mislocalization of the protein. Our data are promising
and with translational potential, as they suggest that allele-
specific therapy can be useful for PXE patients, as well as for
those GACI patients who harbor mutations in ABCC6. In this
context, it should be noted that 4-PBA is a drug that has
already been approved by Food and Drug Administration for
clinical use, and its efficacy in PXE and GACI patients could
be studied in upcoming clinical trials.
MATERIALS AND METHODS
Primary and secondary antibodies
The following primary antibodies were used: anti-human ABCC6:
M6II-7 (rat, 1:100; generous gift from George Scheffer, University
Medical Center, Amsterdam, The Netherlands); anti-mouse Abcc6:
S-20 (rabbit, 1:200); and anti-Na, K-ATPase (chicken, 1:200; Santa
Cruz Biotechnology, Dallas TX). The secondary antibodies used were
Table 1. Summary of the characterization and rescue of disease-causing ABCC6 mutants
Localization in mouse liver Localization in MDCKII cell line
Nonpolarized Polarized
ABCC6
variant
Sf9 transport
activity
Without
treatment
After 4-PBA
treatment
Without
treatment
After 4-PBA
treatment
Without
treatment
After 4-PBA
treatment
ZebrafishþmRNA
rescue (%)
Wild type Active PM1 PM PM PM PM PM 90.6
R1114P Active IC4PM PM (rescue) ICoPM PM (rescue) PM PM 0.0
S1121W Active IC4PM PM (rescue) PM PM PM PM 7.9
R1138Q Active IC4PM IC4PM
(no effect)
IC PM (rescue) PM PM 1.8
V1298F o20% PM ND PM PM PM ND 32.0
T1301I Active IC4PM IC4PM
(no effect)
IC4PM PM (rescue) PM PM 5.1
R1314W1 Active IC4PM PM (rescue) IC PM (rescue) IC4PM PM (rescue) 0.0
G1321S o20% IC ND IC4PM IC4PM
(no effect)
IC IC (no effect) 0.0
R1339C Not stable IC IC (no effect) IC IC (no effect) IC IC (no effect) 0.0
Q1347H Active IC4PM PM (rescue) IC4PM PM (rescue) IC¼ PM IC¼ PM
(no effect)
0.8
R1459C Active PM ND IC¼ PM PM (rescue) ICoPM ICoPM
(no effect)
0.0
delABCC6 o20% IC IC IC IC IC IC ND
R1141X Stop ND ND ND ND ND ND 4.8
Abbreviations: IC, intracellular; ND, not determined; PM, plasma membrane.
1This mutation is associated with both PXE and GACI phenotypes (Nitschke et al., 2012; Li et al., 2013).
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as follows (Life Technologies, Eugene, OR): anti-rat Alexa Fluor 488
(1:250); anti-rabbit Alexa Fluor 594 (1:250); and anti-chicken Alexa
Fluor 594 (1:250).
Mice
All mice were kept under standard laboratory conditions, and
the study was approved by the Institutional Animal Care and Use
Committee of the University of Hawaii and by the Institutional
Animal Care and Use Committee of the RCNS of the Hungarian
Academy of Sciences.
Expression of ABCC6 variants in Sf9 insect cells, vesicular
transport
Expression of ABCC6 variants in Sf9 insect cells and vesicular transport
was performed as described (Sarkadi et al., 1992; Bakos et al., 1998;
Szaka´cs et al., 2001; Ilia´s et al., 2002). Briefly, Sf9 cells were cultured
at 27 1C in TNM-FH insect medium supplied with 10% fetal bovine
serum, 100 U ml 1 penicillin, and 100 mg ml 1 streptomycin. For
transfection of Sf9 cells, BaculoGold kit (BD Biosciences, Durham, NC)
was used. We isolated individual virus clones using the end-point
dilution method. Sf9 membrane vesicles from cells overexpressing wt
or mutant ABCC6 were prepared and incubated with [3H]LTC4
(130 Ci mmol 1; Perkin-Elmer, Waltham, MA) in the presence or
absence of 4 mM MgATP at 37 1C. The transport reaction was
terminated and the vesicles were transferred onto a nitrocellulose
filter. Radioactivity was determined by liquid scintillation counter.
The ABCC6 model (Fu¨lo¨p et al., 2009) was analyzed with the
PyMOL Molecular Graphics System, Version 1.3, Schro¨dinger, LLC.
Expression of ABCC6 variants in MDCKII cells
MDCKII cells were cultured in a humidified 37 1C, 5% CO2
incubator, in DMEM culture medium with 10% fetal bovine serum,
100 U ml 1 penicillin, and 100 mg ml 1 streptomycin either on
standard 24-well plastic plates (for nonpolarized cultures) or on BD
Falcon cell culture inserts (BD Biosciences, Durham, NC; for
polarized cultures). Expression of ABCC6 variants was achieved by
retroviral transfection: Phoenix-Ampho packaging cells were trans-
fected with the recombinant retrovirus vectors containing wt or
mutant ABCC6. The transfection was performed using the calcium
phosphate method. Cell clones overexpressing ABCC6 were selected
by end-point dilution (Sinko´ et al., 2003). For immunocytochemistry,
MDCKII cells were first washed and fixed with 4% paraformaldehyde
and precooled methanol, and they were then incubated with blocking
buffer for 1 hour at room temperature. After removal of the blocking
buffer, samples were incubated with the appropriate primary
antibodies for 2 hours at room temperature. After washing, the cells
were incubated with the secondary antibodies for 1 hour. Nuclei were
stained with 40,6-diamidino-2-phenylindole for 5 minutes. Samples
were kept at 4 1C until microscopic analysis.
Liver-specific expression of ABCC6 variants in mice and
immunohistochemical staining of mouse liver samples
Liver-specific expression of ABCC6 variants in mice and immunohis-
tochemical staining of mouse liver samples were performed as
described in our previous papers (Le Saux et al, 2011; Pomozi
et al., 2013). Briefly, pLIVE plasmid (Mirus Bio, Madison, WI)
containing the wt or mutant ABCC6 was delivered into the mice by
hydrodynamic tail-vein injection (70mg of plasmid DNA in 1.8 ml). At
least four mice were injected with each form of the human ABCC6
cDNA. Mice were killed by standard CO2 procedures 2 days after
hydrodynamic tail vein injections. For immunohistochemistry, 8-mm-
thick frozen sections were prepared from frozen liver tissue, slices
were fixed in methanol, and then washed in Dulbecco’s phosphate-
buffered saline. After incubation in blocking buffer for 1 hour, the
appropriate primary antibodies were added for 90 minutes, followed
by incubation with secondary antibodies for 1 hour. Nuclei were
stained with 40,6-diamidino-2-phenylindole for 5 minutes. Samples
were kept at 4 1C until microscopic analysis.
4-PBA treatment of MDCKII cells and mice
MDCKII cells were cultured in the presence of 1 mM 4-PBA (Tocris
Biosciences, Ellisville, MO). Mice received three intraperitoneal
injections of 4-PBA (100 mg/kg 1 per day) before performing hydro-
dynamic tail-vein injections and additionally received approximate
dosage of 1000 mg/kg 1 per day for 3 days in the drinking water.
Rescue experiments in zebrafish
Rescue experiments in zebrafish were performed as described in our
recent publications (Li et al., 2010; Zhou et al., 2013). Briefly, human
ABCC6 variants were cloned in Bluescript II SKþ vector, and mRNA
was generated by in vitro transcription using the mMessage
mMachine kit (Ambion, Austin, TX). mRNA (2–4 ng per embryo)
was injected into B100 one- to four-cell-stage embryos, together
with 12–18 ng of MO1 morpholino, and the embryonic phenotype
and survival were determined at 3 days after injection.
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